Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

March 31, 2006

Conditions
Colonic DiseasesCancer
Interventions
DRUG

Oxaliplatin

"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."

Trial Locations (4)

87108

Lovelace Sandia Health Systems Dept of Hematology, Albuquerque

87131

University of New Mexico Cancer Center, Albuquerque

87102-3661

Hematology Oncology Associates, Albuquerque

Unknown

New Mexico Veterans Administration Health Care System, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT00250029 - Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen | Biotech Hunter | Biotech Hunter